Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

Abstract

Sofosbuvir plus ribavirin for 12 weeks may be effective in previously untreated patients with HCV genotype 1, 2, or 3 infection. (Funded by Pharmasset and Gilead Sciences; ClinicalTrials.gov number, NCT01260350.).